title: Antihepatitis C virus treatments for HIV-hepatitis C virus coinfected cirrhotic patients: a need to look beyond the sustained viral response.
authors.affiliation: aHôpital Foch, Suresnes bPharmaco-Toxicology Department, Hôpital Bichat, Paris, France.
authors.forename: David
authors.initials: D
authors.lastname: Zucman
authors.forename: Thomas
authors.initials: T
authors.lastname: Sené
authors.forename: Sophie
authors.initials: S
authors.lastname: Hillaire
authors.forename: Jean-Emmanuel
authors.initials: JE
authors.lastname: Kahn
authors.forename: Eric
authors.initials: E
authors.lastname: Farfour
authors.forename: Gilles
authors.initials: G
authors.lastname: Peytavin
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D060085:Coinfection / Q000150:complications / Q000188:drug therapy; D017809:Fatal Outcome; D015658:HIV Infections / Q000150:complications*; D016174:Hepacivirus / Q000302:isolation & purification; D019698:Hepatitis C, Chronic / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D008103:Liver Cirrhosis / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D012367:RNA, Viral / Q000097:blood; D012254:Ribavirin / Q000627:therapeutic use; D000069474:Sofosbuvir / Q000627:therapeutic use; D016896:Treatment Outcome; D019562:Viral Load
chemical_list: D000998:Antiviral Agents; D012367:RNA, Viral; D012254:Ribavirin; D000069474:Sofosbuvir